Phase 2b trial results of padeliporfin (WST11 or Tookad) vascular-targeted photodynamic therapy for partial gland ablation in men with intermediate-risk prostate cancer

Jonathan A. Coleman,Daniel Sjöberg,Quinlan Demac,Catriona ODea,Marlena McGill,Andrew Tracey,Lucas Nogueira,Andrew J. Vickers,Connie Estes,Samson W. Fine,Oguz Akin,John P. Mulhall,Jaspreet S. Sandhu,Brett S. Carver,Vincent P. Laudone,Behfar Ehdaie,Avigdor Scherz,Peter T. Scardino,James A. Eastham

Phase 2b trial results of padeliporfin (WST11 or Tookad) vascular-targeted photodynamic therapy for partial gland ablation in men with intermediate-risk prostate cancer

2021

Jonathan A. Coleman
Daniel Sjöberg
Quinlan Demac
Catriona ODea
Marlena McGill
Andrew Tracey
Lucas Nogueira
Andrew J. Vickers
Connie Estes
Samson W. Fine
Oguz Akin
John P. Mulhall
Jaspreet S. Sandhu
Brett S. Carver
Vincent P. Laudone
Behfar Ehdaie
Avigdor Scherz
Peter T. Scardino
James A. Eastham

e17006Background: Padeliporfin (WST11) vascular-targeted photodynamic therapy (VTP) has shown significant clinical benefit as a localized partial gland ablation (PGA) therapy when compared to activ...

Keywords:

Internal medicine
intermediate risk
Medicine
Oncology
Padeliporfin
Prostate cancer
2019 20 coronavirus outbreak
Coronavirus disease 2019
Photodynamic therapy
severe acute respiratory syndrome coronavirus 2
Ablation

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations